← Trials/Trial dossier/NCT00457769

UnknownPhase 1

Aricept to Improve Functional Tasks in Vascular Dementia

Phase 1 Study of Aricept Plus a Behavioral Strategy to Improve Functional Tasks in Vascular Dementia

Lead sponsor

Kessler Foundation

Asset

Donepezil

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Vascular cognitive impairment / dementia

Key I/E criterion

•Age ≥18

Primary endpoint

•Primary

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAMBarrett2

NCT IDNCT00457769

Timeline

Milestones

Study first posted2007-04-06estimated

Study start2007-05 (month precision)

Last update posted2021-02-17actual

Primary completion2021-12estimated (month precision)

Study completion2021-12estimated (month precision)

Assets

Drug assets

Donepezil

Study populations

Who this study enrolls

Vascular cognitive impairment / dementia

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. I am 18 to100 yrs old.

2. I had one stroke 4 months to 5 yrs ago

3. I am not taking Aricept or other cholinesterase inhibitors (e.g. Exelon, Razadyne) or memantine (Namenda)

Exclusion criteria

1. I have history of dementia and or have been diagnosed with a memory disorder prior to my stroke.

2. I have been on anti-depressants or other cognitive enhancing drugs for less than 3 months and the dose is not stabilized yet.

3. I consume alcohol more than or equivalent of 4 ounces hard liquor weekly.

4. I am taking oral anticholinergic medications like Bethanechol, Bentyl or Detrol.

5. I am a woman of childbearing potential or I am pregnant or a nursing mother.

6. I have a history of chronic vomiting or diarrhea.

7. I am allergic to Aricept.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Memory

Other (unclassified)

Memory

1 endpoint

Secondary/protocol endpoint

To examine whether taking Aricept and actually performing functional tasks improves memory over that provided by a self-generation strategy.

Time frame:24 weeks

ratio, descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Primary: To examine whether taking Aricept results in improvement at remembering steps of functional tasks.

Time frame:12 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Goverover Y, Chiaravalloti N, DeLuca J. The relationship between self-awareness of neurobehavioral symptoms, cognitive functioning, and emotional symptoms in multiple sclerosis. Mult Scler. 2005 Apr;11(2):203-12. doi: 10.1191/1352458505ms1153oa.
PMID15794396via BACKGROUND

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.